Search results for: 'ngs in c2'
- Related search terms
- NGShiv drug resistance
- NGS China
- NGS Informatics Market Forecast to 2027
- ngs testing
- NGS tertiary analysis
-
30 Nov 2020  |  North America  |  Market Research
Geopolitical Instability such as Chinese Naval Expansionism Driving Evolution across the Global Naval Command and Control Market
Future Growth Potential in the Movement of C2 Systems towards Open Architecture and Shared Networks
A command and control (C2) system provides information to maritime decision makers by generating meaningful output pertinent to their operational requirements and mission objectives. If a sensor package identifies a threat, it is relayed to the C2 system, accounting for environmental data from other systems. The C2 system displays and processes all...
$2,450.00
Special Price $1,837.50 save 25 %
-
30 Nov 2017  |  Europe  |  Market Research
Growth Opportunities in European Prenatal Genetic Testing Market, Forecast to 2021
Non-invasive Prenatal Testing (NIPT) Driven by the Adoption of Next Generation Sequencing (NGS) Techniques for Screening is Driving Market Growth
Prenatal genetic tests are predominantly used to test disorders such as aneuploidies in chromosomes 21, 18, 13 and carrier screens. They are gaining momentum in EU due to enhanced assay outcomes through non-invasive methodologies using next generation sequencing (NGS) techniques, increasing number of women choosing to undergo pregnancy at an advanc...
$3,000.00
Special Price $2,250.00 save 25 %
-
18 Feb 2021  |  North America  |  Market Research
Geopolitical Chaos Will Continue to Shape Naval Command and Control Systems
Strategic Partnerships are Essential to Make Inroads into Modernisation and Replacement Programmes
A command and control (C2) system provides information to aid and implement the decision-making process, generating meaningful outputs in order to meet operational requirements and mission objectives. A sensor package may identify a threat that will then be relayed to the C2 system, which will also take into account environmental data from other sy...
$4,950.00
Special Price $3,712.50 save 25 %
-
05 Nov 2024  |  Global  |  Market Research
Generative AI Transforms Enterprise Virtual Assistant Capabilities
Unlocking Enterprise Value to Help Fuel Business Growth
This Frost & Sullivan analysis examines the clinical next-generation sequencing (NGS) industry, covering the different type of products, workflows, and applications for clinical purposes. The global market is projected to grow steadily from 2024 to 2030, achieving significant revenue milestones, driven largely by services and informatics segments. ...
$2,450.00
Special Price $2,082.50 save 15 %
-
20 Jul 2020  |  Global  |  Market Research
RNG Powering the Global Natural Gas Truck and Bus Market, 2020–2030
Governments to Develop/Expand the Fueling Infrastructure Presents Growth Opportunities
The medium duty (MD) and heavy duty (HD) truck and bus market will show strong recovery globally after a major dip in 2020 due to the COVID-19 crisis which will affect production as well as sales across regions. The crisis will also have a profound effect on the adoption of natural gas (NG) powered truck and buses, with China and Europe witnessing ...
$4,950.00
Special Price $3,712.50 save 25 %
-
02 Nov 2022  |  Latin America  |  Market Research
Latin American Commercial Vehicle (CV) Growth Opportunities, Forecast to 2030
Propulsion Alternatives to Diesel will Gain Momentum during the Medium Term of the Forecast Period (2025-2026); the Outlook for the Medium-duty (MD) Segment and Natural Gas (NG) in the Heavy-duty (HD) Segment is Strong
Overall commercial vehicle (CV) units in Latin America (LATAM) are expected to reach 1.5 million units by 2030, growing at a compound annual growth rate (CAGR) of 3.4% between 2021 and 2030. Infrastructure investment, mining development and exports, multimodal transportation projects, and agro-based farm equipment manufacturing will drive industry ...
$4,950.00
Special Price $3,712.50 save 25 %
-
22 Oct 2018  |  North America  |  Market Research
Global Life Sciences Instrumentation and Research Tools Market, Forecast to 2023
Digitalization and M&As to Transform the Current Competitive Structure of the Industry
The global life sciences instrumentation and research tools market is currently going through a transformation driven by ongoing market consolidation and technological innovation. Over the past five years, the industry has witnessed more than 50 mergers and acquisitions (M&A), which have resulted in a market consolidation at the top. Most of these ...
$4,950.00
Special Price $3,712.50 save 25 %
-
03 Oct 2022  |  Global  |  Market Research
Global Prenatal Genetic Testing—Forecast to 2026
Innovation Culture in Screening Drives Prenatal Genetic Testing Growth and Makes it Accessible to More Patients
New technological advances in prenatal genetic testing include the enhancement of the next-generation sequencing (NGS) technology, chromosomal microarray analysis (CMA) tool, and PCR TaqMan. These improve precision and specificity in genome profiling, augment the efficiency and reliability of testing, and streamline workflow. The study will help...
$4,950.00
Special Price $3,712.50 save 25 %
-
13 Jan 2023  |  Global  |  Market Research
Global Life Science Instrumentation and Research Tool Growth Opportunities
Automation and Robotization to Ensure Industrywide Streamlining and Increase Future Growth Potential
New technological advances in life science instrumentation and research tools include the enhancement of next-generation sequencing (NGS) technology, digital PCR, and a wide range of informatics, robotics, and automated solutions. These improve workflow, facilitate and automate tasks, and make better use of workspaces in every area of industry. ...
$4,950.00
Special Price $3,712.50 save 25 %
-
13 Dec 2022  |  Global  |  Technology Research
Companion Diagnostics (CDx): Technology Innovation and Growth Opportunities
The Transition to Precision Medicine is Propelling the Adoption of CDx Platforms.
The concept of companion diagnostics (CDx) was developed when researchers realized that even potent drugs only had an efficacy between 25% and 60%, the lowest being in oncology. Therefore, a clinical pharmacogenetic assay became important to distinguish patients more likely to respond to a drug or at a lesser risk of associated adverse pathophysiol...
$4,950.00
Special Price $3,712.50 save 25 %